Overcoming Boundaries: Interventional Oncology Paving the Way for Cholangiocarcinoma Resection

Abstract

Intrahepatic cholangiocarcinoma (ICC) has been increasing in the United States and other Western countries and carries a very poor prognosis. Currently, the only curative option is surgical resection, which can increase the 5-year survival from 5 to 30%. However, only 15% of cases of ICC are resectable at the time of diagnosis. With the development of new interventional treatment strategies, including radioembolization, chemoembolization, and portal and hepatic venous embolization, interventional radiologists are playing an increasing role in downstaging and improving the survival outcomes of patients who were initially unresectable.

Keywords

cholangiocarcinoma - interventional oncology - downstaging

Publikationsverlauf

Eingereicht: 15. Februar 2024

Angenommen: 24. Juni 2024

Artikel online veröffentlicht:
11. November 2024

• References

• 1 Schartz DA, Porter M, Schartz E. et al. Transarterial yttrium-90 radioembolization for unresectable intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Vasc Interv Radiol 2022; 33 (06) 679-686
• 2 Zhen Y, Liu B, Chang Z, Ren H, Liu Z, Zheng J. A pooled analysis of transarterial radioembolization with yttrium-90 microspheres for the treatment of unresectable intrahepatic cholangiocarcinoma. OncoTargets Ther 2019; 12: 4489-4498
• 3 Edeline J, Touchefeu Y, Guiu B. et al. Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol 2020; 6 (01) 51-59
• 4 Edeline J, Du FL, Rayar M. et al. Glass microspheres 90Y selective internal radiation therapy and chemotherapy as first-line treatment of intrahepatic cholangiocarcinoma. Clin Nucl Med 2015; 40 (11) 851-855
• 5 Bourien H, Palard X, Rolland Y. et al. Yttrium-90 glass microspheres radioembolization (RE) for biliary tract cancer: a large single-center experience. Eur J Nucl Med Mol Imaging 2019; 46 (03) 669-676
• 6 Paz-Fumagalli R, Core J, Padula C. et al. Safety and initial efficacy of ablative radioembolization for the treatment of unresectable intrahepatic cholangiocarcinoma. Oncotarget 2021; 12 (20) 2075-2088
• 7 Sarwar A, Ali A, Ljuboja D. et al. Neoadjuvant yttrium-90 transarterial radioembolization with resin microspheres prescribed using the medical internal radiation dose model for intrahepatic cholangiocarcinoma. J Vasc Interv Radiol 2021; 32 (11) 1560-1568
• 8 Gupta AN, Gordon AC, Gabr A. et al. Yttrium-90 radioembolization of unresectable intrahepatic cholangiocarcinoma: long-term follow-up for a 136-patient cohort. Cardiovasc Intervent Radiol 2022; 45 (08) 1117-1128
• 9 Yu Q, Ungchusri E, Pillai A. et al. Selective internal radiation therapy using yttrium-90 microspheres for treatment of localized and locally advanced intrahepatic cholangiocarcinoma. Eur Radiol 2024; 34 (04) 2374-2383
• 10 Ahmed O, Yu Q, Patel M. et al. Yttrium-90 radioembolization and concomitant systemic gemcitabine, cisplatin, and capecitabine as the first-line therapy for locally advanced intrahepatic cholangiocarcinoma. J Vasc Interv Radiol 2023; 34 (04) 702-709
• 11 Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg 2014; 149 (06) 565-574
• 12 Walker EJ, Simko JP, Nakakura EK, Ko AH. A patient with cholangiocarcinoma demonstrating pathologic complete response to chemotherapy: exploring the role of neoadjuvant therapy in biliary tract cancer. J Gastrointest Oncol 2014; 5 (06) E88-E95
• 13 Gabr A, Riaz A, Johnson GE. et al. Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants. Eur J Nucl Med Mol Imaging 2021; 48 (02) 580-583
• 14 Yu Q, Patel M, Kwak D. et al. Segmental yttrium-90 radioembolization using glass microspheres greater than 400 gray for the treatment of intrahepatic cholangiocarcinoma: a preliminary experience. J Vasc Interv Radiol 2023; 34 (11) 1970-1976.e1
• 15 Young S, Torkian P, Flanagan S, D'Souza D, Sanghvi T, Golzarian J. Intrahepatic cholangiocarcinoma: a dose threshold evaluation in those undergoing transarterial radioembolization. J Gastrointest Oncol 2023; 14 (05) 2202-2211
• 16 Kis B, Shridhar R, Mhaskar R. et al. Radioembolization with yttrium-90 glass microspheres as a first-line treatment for unresectable intrahepatic cholangiocarcinoma-a prospective feasibility study. J Vasc Interv Radiol 2023; 34 (09) 1547-1555
• 17 Chan SL, Chotipanich C, Choo SP. et al. Selective internal radiation therapy with yttrium-90 resin microspheres followed by gemcitabine plus cisplatin for unresectable intrahepatic cholangiocarcinoma: a phase 2 single-arm multicenter clinical trial. Liver Cancer 2022; 11 (05) 451-459
• 18 Buettner S, Braat AJAT, Margonis GA. et al. Yttrium-90 radioembolization in intrahepatic cholangiocarcinoma: a multicenter retrospective analysis. J Vasc Interv Radiol 2020; 31 (07) 1035-1043.e2
• 19 Bargellini I, Mosconi C, Pizzi G. et al. Yttrium-90 radioembolization in unresectable intrahepatic cholangiocarcinoma: results of a multicenter retrospective study. Cardiovasc Intervent Radiol 2020; 43 (09) 1305-1314
• 20 Saxena A, Bester L, Chua TC, Chu FC, Morris DL. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol 2010; 17 (02) 484-491
• 21 Valle J, Wasan H, Palmer DH. et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362 (14) 1273-1281
• 22 Oh DY, Ruth HA, Qin S. et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 2022; 1 (08) EVIDoa2200015.
• 23 Kelley RK, Ueno M, Yoo C. et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 2023; 401 (10391): 1853-1865
• 24 Bisello S, Camilletti AC, Bertini F. et al. Stereotactic radiotherapy in intrahepatic cholangiocarcinoma: A systematic review. Mol Clin Oncol 2021; 15 (02) 1-8
• 25 Hawkins MA, Valle JW, Wasan HS. et al. Addition of stereotactic body radiotherapy (SBRT) to systemic chemotherapy in locally advanced cholangiocarcinoma (CC) (ABC-07): Results from a randomized phase II trial. J Clin Oncol 2024; 42 (16_suppl): 4006-4006
• 26 Guiu B. Portal vein embolization versus Yttrium-90 radioembolization: the race is not always to the swift...the dosimetry-driven tortoise might well win the day!. J Vasc Interv Radiol 2021; 32 (06) 843-844
• 27 Burger I, Hong K, Schulick R. et al. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol 2005; 16 (03) 353-361
• 28 Aliberti C, Carandina R, Sarti D. et al. Chemoembolization with drug-eluting microspheres loaded with doxorubicin for the treatment of cholangiocarcinoma. Anticancer Res 2017; 37 (04) 1859-1863
• 29 Schiffman SC, Metzger T, Dubel G. et al. Precision hepatic arterial irinotecan therapy in the treatment of unresectable intrahepatic cholangiocellular carcinoma: optimal tolerance and prolonged overall survival. Ann Surg Oncol 2011; 18 (02) 431-438
• 30 Nevermann N, Bode J, Vischer M. et al. Perioperative outcome and long-term survival for intrahepatic cholangiocarcinoma after portal vein embolization and subsequent resection: A propensity-matched study. Eur J Surg Oncol 2023; 49 (12) 107100
• 31 Heil J, Korenblik R, Heid F. et al. Preoperative portal vein or portal and hepatic vein embolization: DRAGON collaborative group analysis. Br J Surg 2021; 108 (07) 834-842
• 32 Marino R, Ratti F, Della Corte A. et al. Comparing liver venous deprivation and portal vein embolization for perihilar cholangiocarcinoma: Is it time to shift the focus to hepatic functional reserve rather than hypertrophy?. Cancers (Basel) 2023; 15 (17) 4363